Antibody responses to rhesus cytomegalovirus glycoprotein B in naturally infected rhesus macaques
- PMID: 14645918
- DOI: 10.1099/vir.0.19508-0
Antibody responses to rhesus cytomegalovirus glycoprotein B in naturally infected rhesus macaques
Abstract
Rhesus cytomegalovirus (RhCMV) exhibits strong parallels with human CMV (HCMV) in terms of nucleic and amino acid identities, natural history, and mechanisms of persistence and pathogenesis in its natural host, rhesus macaques (Macaca mulatta). To determine whether this non-human primate model would be useful to assess vaccine strategies for HCMV, host immune responses to RhCMV glycoprotein B (gB) were evaluated in RhCMV-infected monkeys. Total protein extracts were prepared from cells transiently transfected with an expression plasmid for either the full-length gB or a derivative (gBDelta, 1-680 aa) lacking both the transmembrane domain and cytoplasmic tail. Western blot analysis showed identical reactivity of macaque sera with full-length gB and its derivative gBDelta, indicating that the immunodominant epitopes of gB are contained in the extracellular portion of the protein. Using gBDelta extract as a solid phase, a sensitive and specific ELISA was established to characterize gB antibody responses in monkeys acutely and chronically infected with RhCMV. During primary infection (seroconversion), gB-specific antibodies developed concurrently and in parallel with total RhCMV-specific antibodies. However, during chronic infection gB-specific antibody responses were variable. A strong correlation was observed between neutralizing and gB-specific antibody levels in RhCMV-seropositive monkeys. Taken together, the results of this study indicate that, similar to host humoral responses to HCMV gB, anti-gB antibodies are an integral part of humoral immunity to RhCMV infection and probably play an important protective role in limiting the extent of RhCMV infection. Thus, the rhesus macaque model of HCMV infection is relevant for testing gB-based immune therapies.
Similar articles
-
Immunogenicity and protective efficacy of DNA vaccines expressing rhesus cytomegalovirus glycoprotein B, phosphoprotein 65-2, and viral interleukin-10 in rhesus macaques.J Virol. 2007 Feb;81(3):1095-109. doi: 10.1128/JVI.01708-06. Epub 2006 Nov 15. J Virol. 2007. PMID: 17108040 Free PMC article.
-
Pathogenesis of Wild-Type-Like Rhesus Cytomegalovirus Strains following Oral Exposure of Immune-Competent Rhesus Macaques.J Virol. 2022 Feb 9;96(3):e0165321. doi: 10.1128/JVI.01653-21. Epub 2021 Nov 17. J Virol. 2022. PMID: 34788083 Free PMC article.
-
Comparison of vaccination with rhesus CMV (RhCMV) soluble gB with a RhCMV replication-defective virus deleted for MHC class I immune evasion genes in a RhCMV challenge model.Vaccine. 2019 Jan 7;37(2):333-342. doi: 10.1016/j.vaccine.2018.08.043. Epub 2018 Dec 3. Vaccine. 2019. PMID: 30522906
-
Rhesus cytomegalovirus a nonhuman primate model for the study of human cytomegalovirus.Adv Virus Res. 2008;72:207-26. doi: 10.1016/S0065-3527(08)00405-3. Adv Virus Res. 2008. PMID: 19081492 Review.
-
Humoral immune response to human cytomegalovirus infection: diagnostic potential of immunoglobulin class and IgG subclass antibody response to human cytomegalovirus early and late antigens.Clin Investig. 1993 Apr;71(4):270-6. doi: 10.1007/BF00184725. Clin Investig. 1993. PMID: 8386033 Review.
Cited by
-
Host immune responses to a viral immune modulating protein: immunogenicity of viral interleukin-10 in rhesus cytomegalovirus-infected rhesus macaques.PLoS One. 2012;7(5):e37931. doi: 10.1371/journal.pone.0037931. Epub 2012 May 24. PLoS One. 2012. PMID: 22655082 Free PMC article.
-
Convalescent Immunity to Guinea Pig Cytomegalovirus Induces Limited Cross Strain Protection against Re-Infection but High-Level Protection against Congenital Disease.Int J Mol Sci. 2020 Aug 20;21(17):5997. doi: 10.3390/ijms21175997. Int J Mol Sci. 2020. PMID: 32825429 Free PMC article.
-
Neutralizing antibodies to gB based CMV vaccine requires full length antigen but reduced virus neutralization on non-fibroblast cells limits vaccine efficacy in the guinea pig model.Vaccine. 2020 Feb 28;38(10):2340-2349. doi: 10.1016/j.vaccine.2020.01.063. Epub 2020 Jan 31. Vaccine. 2020. PMID: 32008881 Free PMC article.
-
Vaccine-induced control of viral shedding following rhesus cytomegalovirus challenge in rhesus macaques.J Virol. 2011 Mar;85(6):2878-90. doi: 10.1128/JVI.00883-10. Epub 2010 Dec 29. J Virol. 2011. PMID: 21191005 Free PMC article.
-
A heterologous DNA prime/protein boost immunization strategy for rhesus cytomegalovirus.Vaccine. 2008 Nov 5;26(47):6013-25. doi: 10.1016/j.vaccine.2008.07.103. Epub 2008 Aug 27. Vaccine. 2008. PMID: 18760319 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical